214 related articles for article (PubMed ID: 26787381)
1. A Prospective Natural History Study of Mucopolysaccharidosis Type IIIA.
Shapiro EG; Nestrasil I; Delaney KA; Rudser K; Kovac V; Nair N; Richard CW; Haslett P; Whitley CB
J Pediatr; 2016 Mar; 170():278-87.e1-4. PubMed ID: 26787381
[TBL] [Abstract][Full Text] [Related]
2. A prospective one-year natural history study of mucopolysaccharidosis types IIIA and IIIB: Implications for clinical trial design.
Truxal KV; Fu H; McCarty DM; McNally KA; Kunkler KL; Zumberge NA; Martin L; Aylward SC; Alfano LN; Berry KM; Lowes LP; Corridore M; McKee C; McBride KL; Flanigan KM
Mol Genet Metab; 2016 Nov; 119(3):239-248. PubMed ID: 27590925
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal MRI brain volume changes over one year in children with mucopolysaccharidosis types IIIA and IIIB.
Abreu NJ; Selvaraj B; Truxal KV; Moore-Clingenpeel M; Zumberge NA; McNally KA; McBride KL; Ho ML; Flanigan KM
Mol Genet Metab; 2021 Jun; 133(2):193-200. PubMed ID: 33962822
[TBL] [Abstract][Full Text] [Related]
4. Observational Prospective Natural History of Patients with Sanfilippo Syndrome Type B.
Whitley CB; Cleary M; Eugen Mengel K; Harmatz P; Shapiro E; Nestrasil I; Haslett P; Whiteman D; Alexanderian D
J Pediatr; 2018 Jun; 197():198-206.e2. PubMed ID: 29661560
[TBL] [Abstract][Full Text] [Related]
5. An observational, prospective, multicenter, natural history study of patients with mucopolysaccharidosis type IIIA.
Wijburg FA; Aiach K; Chakrapani A; Eisengart JB; Giugliani R; Héron B; Muschol N; O'Neill C; Olivier S; Parker S
Mol Genet Metab; 2022 Feb; 135(2):133-142. PubMed ID: 34991944
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal Natural History of Pediatric Subjects Affected with Mucopolysaccharidosis IIIB.
Okur I; Ezgu F; Giugliani R; Muschol N; Koehn A; Amartino H; Harmatz P; de Castro Lopez MJ; Couce ML; Lin SP; Batzios S; Cleary M; Solano M; Peters H; Lee J; Nestrasil I; Shaywitz AJ; Maricich SM; Kuca B; Kovalchin J; Zanelli E
J Pediatr; 2022 Oct; 249():50-58.e2. PubMed ID: 35709957
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety and clinical outcomes of intrathecal heparan-N-sulfatase in patients with Sanfilippo syndrome type A.
Wijburg FA; Heap F; Rust S; de Ruijter J; Tump E; Marchal JP; Nestrasil I; Shapiro E; Jones SA; Alexanderian D
Mol Genet Metab; 2021 Dec; 134(4):317-322. PubMed ID: 34600820
[TBL] [Abstract][Full Text] [Related]
8. Scoring evaluation of the natural course of mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A).
Meyer A; Kossow K; Gal A; Mühlhausen C; Ullrich K; Braulke T; Muschol N
Pediatrics; 2007 Nov; 120(5):e1255-61. PubMed ID: 17938166
[TBL] [Abstract][Full Text] [Related]
9. Mucopolysaccharidosis Type IIIA presents as a variant of Klüver-Bucy syndrome.
Potegal M; Yund B; Rudser K; Ahmed A; Delaney K; Nestrasil I; Whitley CB; Shapiro EG
J Clin Exp Neuropsychol; 2013; 35(6):608-16. PubMed ID: 23745734
[TBL] [Abstract][Full Text] [Related]
10. Mucopolysaccharidosis type III (Sanfilippo disease) in Sweden: clinical presentation of 22 children diagnosed during a 30-year period.
Malm G; Månsson JE
Acta Paediatr; 2010 Aug; 99(8):1253-7. PubMed ID: 20337777
[TBL] [Abstract][Full Text] [Related]
11. The mutation p.Ser298Pro in the sulphamidase gene (SGSH) is associated with a slowly progressive clinical phenotype in mucopolysaccharidosis type IIIA (Sanfilippo A syndrome).
Meyer A; Kossow K; Gal A; Steglich C; Mühlhausen C; Ullrich K; Braulke T; Muschol N
Hum Mutat; 2008 May; 29(5):770. PubMed ID: 18407553
[TBL] [Abstract][Full Text] [Related]
12. Ability change across multiple domains in mucopolysaccharidosis (Sanfilippo syndrome) type IIIA.
Shapiro EG; Eisengart JB; Whiteman D; Whitley CB
Mol Genet Metab; 2024 Feb; 141(2):108110. PubMed ID: 38151384
[TBL] [Abstract][Full Text] [Related]
13. Anesthetic care and perioperative complications in children with Sanfilipo Syndrome Type A.
Cingi EC; Beebe DS; Whitley CB; Belani KG
Paediatr Anaesth; 2016 May; 26(5):531-8. PubMed ID: 26956723
[TBL] [Abstract][Full Text] [Related]
14. A phase 1/2 study of intrathecal heparan-N-sulfatase in patients with mucopolysaccharidosis IIIA.
Jones SA; Breen C; Heap F; Rust S; de Ruijter J; Tump E; Marchal JP; Pan L; Qiu Y; Chung JK; Nair N; Haslett PAJ; Barbier AJ; Wijburg FA
Mol Genet Metab; 2016 Jul; 118(3):198-205. PubMed ID: 27211612
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of biomarkers for Sanfilippo syndrome.
Saville JT; Flanigan KM; Truxal KV; McBride KL; Fuller M
Mol Genet Metab; 2019; 128(1-2):68-74. PubMed ID: 31104888
[TBL] [Abstract][Full Text] [Related]
16. The natural history of neurocognition in MPS disorders: A review.
Shapiro EG; Eisengart JB
Mol Genet Metab; 2021 May; 133(1):8-34. PubMed ID: 33741271
[TBL] [Abstract][Full Text] [Related]
17. Effects of Trehalose Administration in Patients with Mucopolysaccharidosis Type III.
Mobini M; Radbakhsh S; Kubaski F; Eshraghi P; Vakili S; Vakili R; Abbasifard M; Jamialahmadi T; Rajabi O; Emami SA; Tayarani-Najaran Z; Rizzo M; Eid AH; Banach M; Sahebkar A
Curr Med Chem; 2024; 31(20):3033-3042. PubMed ID: 37038706
[TBL] [Abstract][Full Text] [Related]
18. Clinical overview of children with mucopolysaccharidosis type III A and effect of Risperidone treatment on children and their mothers psychological status.
Kalkan Ucar S; Ozbaran B; Demiral N; Yuncu Z; Erermis S; Coker M
Brain Dev; 2010 Feb; 32(2):156-61. PubMed ID: 19217229
[TBL] [Abstract][Full Text] [Related]
19. Bayesian model of disease progression in mucopolysaccaridosis IIIA.
Marion J; Ruiz J; Saville BR
Stat Med; 2022 Aug; 41(18):3579-3595. PubMed ID: 35567343
[TBL] [Abstract][Full Text] [Related]
20. A novel LC-MS/MS assay for heparan sulfate screening in the cerebrospinal fluid of mucopolysaccharidosis IIIA patients.
Naimy H; Powell KD; Moriarity JR; Wu J; McCauley TG; Haslett PA; Barbier AJ; Qiu Y
Bioanalysis; 2016 Feb; 8(4):285-95. PubMed ID: 26847798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
